SCHEMBL29620469

SCHEMBL29620469

COCCN1Cc2cnccc2C1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
IDH1 O75874 1/20 0.46
PARP1 P09874 2/20 0.45
NFATC1 O95644 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HTT P42858 2/20 0.39
ALOX15 P16050 2/20 0.38
MCL1 Q07820 1/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
TSHR P16473 1/20 0.38
SIRT1 Q96EB6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15164719 0.84 PKN2 (0.42) ALDH1A1IDH1PARP1KDM4EHTT
SCHEMBL29620451 0.81 KDM4E (0.40) KDM4EALOX15NPSR1TSHRSIRT1
SCHEMBL29620463 0.81 KDM4E (0.43) SMN1; SMN2PARP1KDM4EALOX15MAPT
SCHEMBL29620459 0.80 IDH1 (0.40) IDH1KDM4EALOX15NPSR1TSHR
SCHEMBL25225949 0.79 KDM4E (0.59) ALDH1A1SMN1; SMN2PARP1MAPK1HSD17B10
SCHEMBL31750354 0.76 IDH1 (0.49) ALDH1A1IDH1GSK3BMAPK1KDM4E
SCHEMBL11923831 0.75 CYP11B2 (0.41) PARP1NPSR1
SCHEMBL2144299 0.74 PARP1 (0.45) ALDH1A1SMN1; SMN2IDH1PARP1HSD17B10
SCHEMBL15727820 0.74 PARP1 (0.45) ALDH1A1SMN1; SMN2PARP1MAPK1HSD17B10
SCHEMBL30434602 0.74 PARP1 (0.45) ALDH1A1SMN1; SMN2IDH1PARP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114555597-B Isocitrate Dehydrogenase (IDH) inhibitors 浙江迈同生物医药有限公司 2024-06-04 CN claimed
EP-4041732-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) 2022-08-17 EP claimed
CN-114555597-A Isocitrate Dehydrogenase (IDH) inhibitors 浙江迈同生物医药有限公司 2022-05-27 CN claimed
US-12441725-B2 ISO-citrate dehydrogenase (IDH) inhibitor ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) 2025-10-14 US disclosed
US-20240116917-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) 2024-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116917-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR IDH2, IDH3A, IDH1 ALDH1A1 538/4885SMN1; SMN2 3453/4885IDH1 3/4885
US-12441725-B2 ISO-citrate dehydrogenase (IDH) inhibitor IDH2, IDH3A, IDH1 ALDH1A1 538/4885SMN1; SMN2 3453/4885IDH1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.